A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients.

被引：0
|
作者：
Burckart, G. [1 ]
Cavaille-Coll, M. [2 ]
Duong, A. [3 ]
Hothem, L. [4 ]
Albrecht, R. [2 ]
机构：
[1] US FDA, Off Clin Pharmacol, Off Translat Sci, CDER, Silver Spring, MD USA
[2] US FDA, Div Transplant & Opthalmol Prod, Off New Drugs, CDER, Silver Spring, MD USA
[3] Tauro Univ, New York, NY USA
[4] Univ N Carolina, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2018年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B245
引用
收藏
页码：714 / 714
页数：1
相关论文
共 44 条
  • [41] Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development (vol 19, pg 131, 2024)
    Mease, Catherine
    Miller, Kathleen L.
    Fermaglich, Lewis J.
    Best, Jeanine
    Liu, Gumei
    Torjusen, Erika
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [42] Therapeutic Drug Monitoring of Vancomycin in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary Excretion Classification System (SECS)
    Arabyat, Majd
    Abdul-Sattar, Ahmad
    Al-Fararjah, Feras
    Al-Ghazawi, Ahmad
    Rabayah, Ayman
    Al-Hasassnah, Rakan
    Mohmmad, Walid
    Al-Adham, Ibrahim
    Hamadi, Salim
    Idkaidek, Nasir
    DRUG RESEARCH, 2022, 72 (08) : 441 - 448
  • [43] Therapeutic Drug Monitoring of Ticagrelor in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class IV Drugs of Salivary Excretion Classification System (SECS).
    Khalil, Mohammed
    Al-Saleh, Akram
    Makhamreh, Hana
    Tayem, Rabab
    Abufarah, Mohammad
    Zubi, Abdullah
    Najib, Omaimah
    Bader, Mohammad
    Najib, Naji
    Alfayoumi, Suliman
    Idkaidek, Nasir
    JOURNAL OF RESEARCH IN PHARMACY, 2022, 26 (05): : 1411 - 1419
  • [44] Levetiracetam dosing in continuous renal replacement therapy: A systematic review and development of a novel pharmacokinetic model to optimise dosing in critically ill patients. Do recommended doses achieve therapeutic drug concentrations?
    Sweatman, James
    Al-Mahdi, Sarraa
    Lonsdale, Dagan O.
    Leaver, Susannah
    Rhodes, Andrew
    JOURNAL OF THE INTENSIVE CARE SOCIETY, 2025,
12345